Professor
Vibeke Andersen
Molecular Diagnostics & Clinical Research, Hospital of Southern Jutland, Aabenraa
Projekt styring | ||
Projekt status | Active | |
Data indsamlingsdatoer | ||
Start | 01.10.2010 | |
Slut | 01.04.2023 | |
The aim of the project is to identify genetic markers, which are associated with the treatment efficacy of TNF inhibitor treatment.
Background:
Rheumatoid arthritis (RA), psoriasis (PSA) and inflammatory bowel disease (IBD) are autoimmune diseases. The diseases share several similarities, and there are common genetic pathways involved in the etiology. Severe cases of RA, PSA and IBD are treated with TNF inhibitor. This treatment has significant side effects and one third of the patients have no effect of the treatment. There is an increasing understanding of the concept, that genetic may impact tratment effects. However, there are only sparsely data concerning genetic predictors of the treatment results for TNF inhibitor.
Aim:
The aim of the project is...
to identify genetic markers, which are associated with the treatment efficacy of TNF inhibitor treatment
Our hypothesis is...
that genetic markers can predict the effect of TNF inhibitor treatment in patients with RA, PSA and IBD
This knowledge can be used to optimize the treatment of the individual patient (personalized treatment). Thereby, patients who are most likely to benefit from the treatment can be selected for anti-TNF treatment
Blood samples analysed for tuberculosis antibodies from Danish laboratories have been collected since September 2009 and so far blood samples from approx. 30.000 patients have been collected in our biobank. Samples from patients with RA, PSA and IBD have been identified through the databases Danbio, Dermbio and The National Patient Registry. Cohorts of 538 patients with RA, 482 patients with Celiac Disease (CD) and 256 patients with Ulcerative colitis (UC) have been established. Replication cohorts of patients with RA and IBD and a new cohort of PSA are about to be established.
The following data is retrieved from Danbio, Dermbio and/or the patient's medical records: Diagnosis, treatment response, age, gender, CD location and behaviour and UC distribution, course of the disease, age at diagnosis, smoking status at diagnosis, smoking status at treatment, operations, concomitant medication and familiar disposition.
Organmedical Clinic, Hospital of Southern Jutland, Aabenraa and Institute of Regional Health Research, University of Southern Denmark
Statens Serum Institut
National Research Centre for the Working Environment, Copenhagen
Department of Rheumatology, Frederiksberg Hospital
Department of Internal Medicine, Regional Hospital Viborg
Hospital of Southern Jutland, Institute of Regional Health Research, University of Southern Denmark
Dermbio, represented by Department of Dermatology, Roskilde Hospital